SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on July 5, 2002; DOI 10.1182/blood-2002-04-1258. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-04-1258v1 101/1/6    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Byrd, J. C. Articles by Larson, R. A. Search for Related Content PubMed PubMed Citation Articles by Byrd, J. C. Articles by Larson, R. A. Related Collections Plenary Papers Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 January 2003, Vol. 101, No. 1, pp. 6-14 PLENARY PAPER Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) John C. Byrd, Bercedis L. Peterson, Vicki A. Morrison, Kathleen Park, Robert Jacobson, Eva Hoke, James W. Vardiman, Kanti Rai, Charles A. Schiffer, and Richard A. Larson From the Division of Hematology-Oncology, Department of Medicine, The Ohio State University, Columbus; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC; Sections of Hematology-Oncology and Infectious Disease, Minneapolis Veterans Affairs Medical Center, MN; Division of Hematology-Oncology, Department of Medicine, Walter Reed Army Medical Center, Washington, DC; Division of Hematology-Oncology, Good Samaritan Hospital, West Palm Beach, FL; Department of Pathology and Department of Medicine, The University of Chicago, IL; Division of Hematology-Oncology, Long Island Jewish Medical Center, New Hyde Park, NY; Division of Hematology-Oncology, Department of Medicine, Wayne State University School of Medicine, Detroit, MI. Recent studies have suggested that rituximab has clinical activity and modulates antiapoptotic proteins associated with drug resistance in chronic lymphocytic leukemia (CLL). We performed a randomized phase 2 study to determine the efficacy, safety, and optimal administration schedule of rituximab with fludarabine in previously untreated CLL patients. Patients were randomized to receive either 6 monthly courses of fludarabine concurrently with rituximab followed 2 months later by 4 weekly doses of rituximab for consolidation therapy or sequential fludarabine alone followed 2 months later by rituximab consolidation therapy. A total of 104 patients were randomized to the concurrent (n = 51) and sequential (n = 53) regimens. During the induction portion of treatment, patients receiving the concurrent regimen experienced more grade 3 or 4 neutropenia (74% versus 41%) and grade 3 or 4 infusion-related toxicity (20% versus 0%) as compared with the sequential arm. The consolidation rituximab therapy was tolerated well in both arms. All other toxicities were similar in the 2 arms. The overall response rate with the concurrent regimen was 90% (47% complete response [CR], 43% partial response [PR]; 95% confidence interval [CI], 0.82-0.98) compared with 77% (28% CR, 49% PR; 95% CI, 0.66-0.99) with the sequential regimen. With a median follow-up time of 23 months, the median response duration and survival have not been reached for either regimen. Rituximab administered concurrently with fludarabine in previously untreated CLL patients demonstrates marked clinical efficacy and acceptable toxicity. Phase 3 studies using this combination approach for patients with CLL are warranted. © 2003 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia Luca Castagna, Barbara Sarina, Armando Santoro, John C. Byrd, Kanti Rai, and Richard A. Larson Blood 2003 102: 2309-2310. [Full Text] [PDF] This article has been cited by other articles: S. O'Brien, J. O. Moore, T. E. Boyd, L. M. Larratt, A. B. Skotnicki, B. Koziner, A. A. Chanan-Khan, J. F. Seymour, J. Gribben, L. M. Itri, et al. 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen J. Clin. Oncol., November 1, 2009; 27(31): 5208 - 5212. [Abstract] [Full Text] [PDF] W. U. Knauf, T. Lissichkov, A. Aldaoud, A. Liberati, J. Loscertales, R. Herbrecht, G. Juliusson, G. Postner, L. Gercheva, S. Goranov, et al. Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia J. Clin. Oncol., September 10, 2009; 27(26): 4378 - 4384. [Abstract] [Full Text] [PDF] C. S. Tam, T. D. Shanafelt, W. G. Wierda, L. V. Abruzzo, D. L. Van Dyke, S. O'Brien, A. Ferrajoli, S. A. Lerner, A. Lynn, N. E. Kay, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience Blood, July 30, 2009; 114(5): 957 - 964. [Abstract] [Full Text] [PDF] S. P. Treon, A. R. Branagan, L. Ioakimidis, J. D. Soumerai, C. J. Patterson, B. Turnbull, P. Wasi, C. Emmanouilides, S. R. Frankel, A. Lister, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia Blood, April 16, 2009; 113(16): 3673 - 3678. [Abstract] [Full Text] [PDF] W. G. Wierda, S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K.-A. Do, G. Garcia-Manero, J. Cortes, D. Thomas, C. Koller, et al. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment J. Clin. Oncol., April 1, 2009; 27(10): 1637 - 1643. [Abstract] [Full Text] [PDF] B. D. Cheson and M. J. Rummel Bendamustine: Rebirth of an Old Drug J. Clin. Oncol., March 20, 2009; 27(9): 1492 - 1501. [Abstract] [Full Text] [PDF] N. Lamanna, J. G. Jurcic, A. Noy, P. Maslak, A. N. Gencarelli, K. S. Panageas, M. L. Heaney, R. J. Brentjens, D. W. Golde, D. A. Scheinberg, et al. Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses J. Clin. Oncol., February 1, 2009; 27(4): 491 - 497. [Abstract] [Full Text] [PDF] K. A. Foon, M. Boyiadzis, S. R. Land, S. Marks, A. Raptis, L. Pietragallo, D. Meisner, A. Laman, M. Sulecki, A. Butchko, et al. Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia J. Clin. Oncol., February 1, 2009; 27(4): 498 - 503. [Abstract] [Full Text] [PDF] S. S. Oberoi and R. M. Abou Jawde Is Alemtuzumab Really the Single Active Agent for Treatment of Chronic Lymphocytic Leukemia? J. Clin. Oncol., December 10, 2008; 26(35): 5827 - 5828. [Full Text] [PDF] C. S. Tam, S. O'Brien, W. Wierda, H. Kantarjian, S. Wen, K.-A. Do, D. A. Thomas, J. Cortes, S. Lerner, and M. J. Keating Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood, August 15, 2008; 112(4): 975 - 980. [Abstract] [Full Text] [PDF] L. Nieuwenhuizen, F. J. Verzijlbergen, E. Wiltink, J. C. Grutters, and D. H. Biesma A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma Haematologica, August 1, 2008; 93(8): 1267 - 1269. [Full Text] [PDF] A. Gowda, J. Roda, S.-R. A. Hussain, A. Ramanunni, T. Joshi, S. Schmidt, X. Zhang, A. Lehman, D. Jarjoura, W. E. Carson, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro Blood, May 1, 2008; 111(9): 4723 - 4730. [Abstract] [Full Text] [PDF] R. K. Oldham and R. O. Dillman Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress J. Clin. Oncol., April 10, 2008; 26(11): 1774 - 1777. [Full Text] [PDF] A. A. Chanan-Khan and B. D. Cheson Lenalidomide for the Treatment of B-Cell Malignancies J. Clin. Oncol., March 20, 2008; 26(9): 1544 - 1552. [Abstract] [Full Text] [PDF] B. Coiffier, S. Lepretre, L. M. Pedersen, O. Gadeberg, H. Fredriksen, M. H. J. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study Blood, February 1, 2008; 111(3): 1094 - 1100. [Abstract] [Full Text] [PDF] S. O'Brien New Agents in the Treatment of CLL Hematology, January 1, 2008; 2008(1): 457 - 464. [Abstract] [Full Text] [PDF] W. G. Wierda Treatments for Patients with Chronic Lymphocytic Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 297 - 305. [Abstract] [Full Text] [PDF] K. A. Blum, D. Young, S. Broering, M. S. Lucas, B. Fischer, T. S. Lin, M. R. Grever, and J. C. Byrd Computed Tomography Scans Do Not Improve the Predictive Power of 1996 National Cancer Institute Sponsored Working Group Chronic Lymphocytic Leukemia Response Criteria J. Clin. Oncol., December 10, 2007; 25(35): 5624 - 5629. [Abstract] [Full Text] [PDF] P. Hillmen, A. B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, and J. Mayer Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia J. Clin. Oncol., December 10, 2007; 25(35): 5616 - 5623. [Abstract] [Full Text] [PDF] C. E. Dearden Role of antibody therapy in lymphoid malignancies Br. Med. Bull., September 1, 2007; 83(1): 275 - 290. [Abstract] [Full Text] [PDF] L. H. Sehn, J. Donaldson, A. Filewich, C. Fitzgerald, K. K. Gill, N. Runzer, B. Searle, S. Souliere, J. J. Spinelli, J. Sutherland, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting Blood, May 15, 2007; 109(10): 4171 - 4173. [Abstract] [Full Text] [PDF] S. O'Brien, J. O. Moore, T. E. Boyd, L. M. Larratt, A. Skotnicki, B. Koziner, A. A. Chanan-Khan, J. F. Seymour, R. G. Bociek, S. Pavletic, et al. Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia J. Clin. Oncol., March 20, 2007; 25(9): 1114 - 1120. [Abstract] [Full Text] [PDF] I. W. Flinn, D. S. Neuberg, M. R. Grever, G. W. Dewald, J. M. Bennett, E. M. Paietta, M. A. Hussein, F. R. Appelbaum, R. A. Larson, D. F. Moore Jr, et al. Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 J. Clin. Oncol., March 1, 2007; 25(7): 793 - 798. [Abstract] [Full Text] [PDF] M. R. Grever, D. M. Lucas, G. W. Dewald, D. S. Neuberg, J. C. Reed, S. Kitada, I. W. Flinn, M. S. Tallman, F. R. Appelbaum, R. A. Larson, et al. Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997 J. Clin. Oncol., March 1, 2007; 25(7): 799 - 804. [Abstract] [Full Text] [PDF] N. E. Kay, S. M. Geyer, T. G. Call, T. D. Shanafelt, C. S. Zent, D. F. Jelinek, R. Tschumper, N. D. Bone, G. W. Dewald, T. S. Lin, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia Blood, January 15, 2007; 109(2): 405 - 411. [Abstract] [Full Text] [PDF] T. D. Shanafelt and N. E. Kay Comprehensive Management of the CLL Patient: A Holistic Approach Hematology, January 1, 2007; 2007(1): 324 - 331. [Abstract] [Full Text] [PDF] V. A. Morrison Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia Hematology, January 1, 2007; 2007(1): 332 - 338. [Abstract] [Full Text] [PDF] P. Venugopal and S. A. Gregory Lymphoproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 265 - 297. [Full Text] [PDF] A. Chanan-Khan, K. C. Miller, L. Musial, D. Lawrence, S. Padmanabhan, K. Takeshita, C. W. Porter, D. W. Goodrich, Z. P. Bernstein, P. Wallace, et al. Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study J. Clin. Oncol., December 1, 2006; 24(34): 5343 - 5349. [Abstract] [Full Text] [PDF] T. D. Shanafelt, J. C. Byrd, T. G. Call, C. S. Zent, and N. E. Kay Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med, September 19, 2006; 145(6): 435 - 447. [Abstract] [Full Text] [PDF] K. W. L. Yee and S. M. O'Brien Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2006; 81(8): 1105 - 1129. [Abstract] [Full Text] [PDF] T. Robak, J. Z. Blonski, J. Gora-Tybor, K. Jamroziak, J. Dwilewicz-Trojaczek, A. Tomaszewska, L. Konopka, B. Ceglarek, A. Dmoszynska, M. Kowal, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2) Blood, July 15, 2006; 108(2): 473 - 479. [Abstract] [Full Text] [PDF] F. Ravandi, J. L. Jorgensen, S. M. O'Brien, S. Verstovsek, C. A. Koller, S. Faderl, F. J. Giles, A. Ferrajoli, W. G. Wierda, S. Odinga, et al. Eradication of minimal residual disease in hairy cell leukemia Blood, June 15, 2006; 107(12): 4658 - 4662. [Abstract] [Full Text] [PDF] M. Alfonso-Perez, S. Lopez-Giral, N. E. Quintana, J. Loscertales, P. Martin-Jimenez, and C. Munoz Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia J. Leukoc. Biol., June 1, 2006; 79(6): 1157 - 1165. [Abstract] [Full Text] [PDF] R. A. Larson, R. M. Stone, R. J. Mayer, and C. A. Schiffer Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clin. Cancer Res., June 1, 2006; 12(11): 3556s - 3563s. [Abstract] [Full Text] [PDF] C. S. Tam and J. F. Seymour The infectious consequences of rituximab addition to fludarabine-containing regimens. Blood, April 1, 2006; 107(7): 3013 - 3014. [Full Text] [PDF] N. E. Kay Treatment and evaluation of CLL: a complicated affair Blood, February 1, 2006; 107(3): 848 - 848. [Full Text] [PDF] J. C. Byrd, J. G. Gribben, B. L. Peterson, M. R. Grever, G. Lozanski, D. M. Lucas, B. Lampson, R. A. Larson, M. A. Caligiuri, and N. A. Heerema Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy J. Clin. Oncol., January 20, 2006; 24(3): 437 - 443. [Abstract] [Full Text] [PDF] T.-H. Liu, A. Raval, S.-S. Chen, J. J. Matkovic, J. C. Byrd, and C. Plass CpG Island Methylation and Expression of the Secreted Frizzled-Related Protein Gene Family in Chronic Lymphocytic Leukemia Cancer Res., January 15, 2006; 66(2): 653 - 658. [Abstract] [Full Text] [PDF] W. G. Wierda Current and Investigational Therapies for Patients with CLL Hematology, January 1, 2006; 2006(1): 285 - 294. [Abstract] [Full Text] [PDF] B. L. Abbott Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment Oncologist, January 1, 2006; 11(1): 21 - 30. [Abstract] [Full Text] [PDF] A. Chanan-Khan, K. C. Miller, K. Takeshita, A. Koryzna, K. Donohue, Z. P. Bernstein, A. Mohr, D. Klippenstein, P. Wallace, J. B. Zeldis, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL) Blood, November 15, 2005; 106(10): 3348 - 3352. [Abstract] [Full Text] [PDF] R. Marasca, R. Maffei, M. Morselli, P. Zucchini, I. Castelli, S. Martinelli, M. Fontana, S. Ravanetti, M. Curotti, G. Leonardi, et al. Immunoglobulin Mutational Status Detected through Single-Round Amplification of Partial VH Region Represents a Good Prognostic Marker for Clinical Outcome in Chronic Lymphocytic Leukemia J. Mol. Diagn., November 1, 2005; 7(5): 566 - 574. [Abstract] [Full Text] [PDF] T. Elter, P. Borchmann, H. Schulz, M. Reiser, S. Trelle, R. Schnell, M. Jensen, P. Staib, T. Schinkothe, H. Stutzer, et al. Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial J. Clin. Oncol., October 1, 2005; 23(28): 7024 - 7031. [Abstract] [Full Text] [PDF] W. G. Wierda, T. J. Kipps, and M. J. Keating Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332. [Abstract] [Full Text] [PDF] D. G. Maloney Immunotherapy for Non-Hodgkin's Lymphoma: Monoclonal Antibodies and Vaccines J. Clin. Oncol., September 10, 2005; 23(26): 6421 - 6428. [Abstract] [Full Text] [PDF] L. D. Kaplan, J. Y. Lee, R. F. Ambinder, J. A. Sparano, E. Cesarman, A. Chadburn, A. M. Levine, and D. T. Scadden Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 Blood, September 1, 2005; 106(5): 1538 - 1543. [Abstract] [Full Text] [PDF] S. Mantha, M. I. Jacobs, and D. G. Savage Unusual Leukemia Presentations: CASE 3. Type I IgG{lambda} Cryoglobulinemia Associated With Chronic Lymphocytic Leukemia J. Clin. Oncol., August 20, 2005; 23(24): 5841 - 5843. [Full Text] [PDF] T. S. Lin, M. R. Grever, and J. C. Byrd Changing the Way We Think About Chronic Lymphocytic Leukemia J. Clin. Oncol., June 20, 2005; 23(18): 4009 - 4012. [Full Text] [PDF] M. J. Keating, S. O'Brien, M. Albitar, S. Lerner, W. Plunkett, F. Giles, M. Andreeff, J. Cortes, S. Faderl, D. Thomas, et al. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia J. Clin. Oncol., June 20, 2005; 23(18): 4079 - 4088. [Abstract] [Full Text] [PDF] T. D. Shanafelt, Y. K. Lee, N. D. Bone, A. K. Strege, V. L. Narayanan, E. A. Sausville, S. M. Geyer, S. H. Kaufmann, and N. E. Kay Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine Blood, March 1, 2005; 105(5): 2099 - 2106. [Abstract] [Full Text] [PDF] M.S. Czuczman, A. Koryzna, A. Mohr, C. Stewart, K. Donohue, L. Blumenson, Z.P. Bernstein, P. McCarthy, A. Alam, F. Hernandez-Ilizaliturri, et al. Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma J. Clin. Oncol., February 1, 2005; 23(4): 694 - 704. [Abstract] [Full Text] [PDF] J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood, February 1, 2005; 105(3): 959 - 967. [Abstract] [Full Text] [PDF] M. Hallek and On Behalf Of The German CLL Study Group Chronic Lymphocytic Leukemia (CLL): First-Line Treatment Hematology, January 1, 2005; 2005(1): 285 - 291. [Abstract] [Full Text] [PDF] M. Ghielmini Multimodality Therapies and Optimal Schedule of Antibodies: Rituximab in Lymphoma as an Example Hematology, January 1, 2005; 2005(1): 321 - 328. [Abstract] [Full Text] [PDF] E. Montserrat CLL therapy: progress at last! Blood, January 1, 2005; 105(1): 2 - 3. [Full Text] [PDF] J. C. Byrd, K. Rai, B. L. Peterson, F. R. Appelbaum, V. A. Morrison, J. E. Kolitz, L. Shepherd, J. D. Hines, C. A. Schiffer, and R. A. Larson Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 Blood, January 1, 2005; 105(1): 49 - 53. [Abstract] [Full Text] [PDF] M. R. Smith, F. Jin, and I. Joshi Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts Mol. Cancer Ther., December 1, 2004; 3(12): 1693 - 1699. [Abstract] [Full Text] [PDF] J. C. Byrd, J. G. Gribben, B. Peterson, M. R. Grever, G. Lozanski, D. M. Lucas, R. A. Larson, M. A. Caligiuri, and N. A. Heerema Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 476 - 476. [Abstract] A. K. Gopal, J. M. Pagel, N. Hedin, and O. W. Press Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism Blood, May 1, 2004; 103(9): 3516 - 3520. [Abstract] [Full Text] [PDF] T. D. Shanafelt and T. G. Call Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia Mayo Clin. Proc., March 1, 2004; 79(3): 388 - 398. [Abstract] [PDF] T. D. Shanafelt, S. M. Geyer, and N. E. Kay Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL Blood, February 15, 2004; 103(4): 1202 - 1210. [Abstract] [Full Text] [PDF] J. C. Byrd, S. Stilgenbauer, and I. W. Flinn Chronic Lymphocytic Leukemia Hematology, January 1, 2004; 2004(1): 163 - 183. [Abstract] [Full Text] [PDF] V. A. Morrison In Reply: J. Clin. Oncol., October 1, 2003; 21(19): 3709 - 3710. [Full Text] [PDF] L. Castagna, B. Sarina, A. Santoro, J. C. Byrd, K. Rai, and R. A. Larson Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia Blood, September 15, 2003; 102(6): 2309 - 2310. [Full Text] [PDF] M. Coleman, D. M. Goldenberg, A. B. Siegel, J. C. Ketas, M. Ashe, J. M. Fiore, and J. P. Leonard Epratuzumab: Targeting B-Cell Malignancies through CD22 Clin. Cancer Res., September 1, 2003; 9(10): 3991s - 3994s. [Abstract] [Full Text] R. Bannerji, S. Kitada, I. W. Flinn, M. Pearson, D. Young, J. C. Reed, and J. C. Byrd Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance J. Clin. Oncol., April 15, 2003; 21(8): 1466 - 1471. [Abstract] [Full Text] [PDF] M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps Biology and Treatment of Chronic Lymphocytic Leukemia Hematology, January 1, 2003; 2003(1): 153 - 175. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020